New data on rose bengal therapy show promise for treating infectious keratitis, advancing clinical use plans.

Provectus Biopharmaceuticals and its subsidiary VisiRose presented new research at ARVO 2026 on rose bengal photodynamic antimicrobial therapy (RB-PDAT) for infectious keratitis and other eye infections. The REAGIR trial, a large randomized controlled study, showed a favorable directional signal for RB-PDAT versus the standard treatment natamycin, especially in fungal keratitis caused by Fusarium. Additional studies highlighted how corneal biochemistry affects treatment, melanin-related resistance in Aspergillus infections, rose bengal’s inhibition of MRSA biofilms, and the benefits of repeated RB-PDAT treatments. These findings support further clinical trials to optimize treatment protocols and advance RB-PDAT toward broader clinical use.